Navigation Links
Delcath Systems Names Michael D. Dellario as Vice President, Global Marketing
Date:3/1/2010

pany specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of primary and metastatic liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer agents to the liver while controlling the systemic exposure of those agents.  In addition to its fully enrolled Phase III metastatic melanoma study, the Company is currently conducting trials to treat other forms of tumor metastases to the liver. The Company maintains a broad intellectual property portfolio on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Eamonn Hobbs Appointed President & CEO of Delcath Systems, Inc.
2. Delcath Systems Receives Preliminary Notification of Inclusion in Russell 3000(R) Index
3. Delcath Enters Agreement to Sell 869,565 Units
4. Delcath Systems Granted Third Orphan Drug Designation
5. Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
7. Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors
8. Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors
9. Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
10. New Online Tutorials for NCBI resources BioSystems and DCODE
11. American Medical Systems and Tissue Genesis Sign $1.1 Million Collaboration Deal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015 China Cord Blood Corporation ... leading provider of cord blood collection, laboratory ... services, today announced that the Company has filed its ... and Exchange Commission. The filed Form 20-F includes audited ... 2015. The Form 20-F can be accessed by visiting ...
(Date:7/30/2015)... ... , ... Ralco is honored to announce that it is the primary sponsor ... August 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the ... their daily lives. This unique exhibit also features a birthing center for fair goers ...
(Date:7/30/2015)... , July 30, 2015   GenoSpace ... for the interpretation and analysis of genomic and ... Fischer has joined the company as Vice ... - http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace ... to integrate, interpret, analyze and explore complex sets ...
(Date:7/30/2015)... ... , ... The 2015 Market Research Report on the Global Propanol Industry ... Propanol market with a focus on the Chinese situation. Major companies included in the ... Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3
... September 6, 2011 , Gains US ... Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the ... has entered into an exclusive license agreement with the ... adeno-associated virus serotype 5 (AAV5)-based gene therapy vectors for ...
... new kind of cloaking material that can render ... this design can,t translate into an invisibility cloak ... in diagnostics, security, and communication. The cloak, ... engineering at Northwestern,s McCormick School of Engineering and ...
... , , , , , , ... , , AUDIO: ... the potential impact... , Click here for more information. ... , , , , , ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health 2Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health 3Hiding objects with a terahertz invisibility cloak 2MIABE standard opens up new opportunities in drug discovery 2MIABE standard opens up new opportunities in drug discovery 3
(Date:7/31/2015)... de julio de 2015 BGI llevará a cabo ... del 22 al 25 de octubre de 2015, en ... conferencia celebra su décimo aniversario este año. Desde su ... de las reuniones anuales más influyentes del mundo en ... las conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... Die 10. internationale Konferenz zu Genomik (ICG-10, ... vom 22. bis 25. Oktober 2015 in ... Die Konferenz feiert in diesem Jahr ihr ... ICG weltweit zu einem der einflussreichsten jährlichen Treffen ... dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... Biotechnology: Principles and Applications of Recombinant DNA is ... up to date with the latest findings and ... "It has been estimated that worldwide there ... of thousands of scientists. When the exciting ...
... Columbus, OH Researchers from the Ohio State University ... the single nucleotide polymorphisms (SNPs) that affect warfarin dose. ... Genotyping of SNPs Influencing Warfarin Drug Response by SELDI-TOF ... the Journal of Molecular Diagnostics . Warfarin ...
... LAS VEGAS, Nev. Every 13 minutes a woman loses ... than 27,000 men died from prostate cancer. These powerful statistics ... millions of dollars in financial support from the National Cancer ... when estrogen metabolism is out of balance it can start ...
Cached Biology News:New edition of ASM Press biotechnology text announced 2Supplement blocks the initiation of breast cell mutations by estrogens 2
... / Mount is the standard water based ... especially for the permanent preservation of peroxidase ... is easy to use and exhibits excellent ... first aqueous mounting medium that permits the ...
... Immunogen: Synthetic peptide derived from an ... protein. Specificity: Specific for the ... WNT2B/WNT13 proteins. Recognizes both human WNT13A ... Human Rat (positive controls: mouse WNT2B/WNT13-pCMV-tag2-transfected ...
Immunogen: Heat inactivated bacterial cells of Salmonella enteriditis,paratyphi and typhimurium Storage: 4 C...
Immunogen: Secretory component isolated from human colostrum. Storage: 4 C...
Biology Products: